Role of Complement System in Atherosclerosis;Kompleman Sisteminin Aterosklerozdaki Rolü

Turk Kardiyoloji Dernegi Arsivi

Volumn 32, Issue 1, 2004, Pages 28-37

  Hergenç, Gülay ^a,b  

^a YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Acylation stimulating protein; Atherosclerosis; C3; Complement system; Inflammation

Indexed keywords

ACYLATION STIMULATING PROTEIN; APOLIPOPROTEIN A1; AUTACOID; CHEMOATTRACTANT; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; KININOGEN; LIPID; LIPOPROTEIN; OPSONIN; PEPTIDE; REGULATOR PROTEIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANGIOGENESIS; ANTIGEN ANTIBODY COMPLEX; ATHEROSCLEROSIS; BLOOD CLOTTING; CHRONIC INFLAMMATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; FIBRINOLYSIS; FOAM CELL; GLUCOSE TRANSPORT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MALE; NEUTROPHIL; PREDICTION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 1142303810     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Libby P: Inflammation in atherosclerosis. Nature 2002; 420: 868-74
2. Meroni PL, Luzzana C, Ventura D: Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol 2002; 23: 263-77
3. Pasqui AL, Puccetti L, Bova G, et al: Relationship between serum complement and different lipid disorders. Clin Exp Med 2002; 2: 33-8
4. Heilbronn LK, Clifton PM: C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. J Nutr Biochem 2002; 13: 316-21
5. Mack C, Jungermann K, Gotze O, Schieferdecker HL: Anaphylatoxin C5a actions in rat liver: synergistic enhancement by C5a of lipopolysaccharide-dependent alpha(2)-macroglobulin gene expression in hepatocytes via IL-6 release from Kupffer cells. J Immunol 2001; 167: 3972-9
6. Kiliçturgay K: Immunoloji. 2. Baski. Kompleman Sistemi Istanbul, Adilna Sanovel, 2000
7. Frank MM: Complement and Kinin. In: Stites DP, Terr AI, Parslow TG (eds). Basic and Clinical Immunology. Beirut, Appleton and Lange, 1999; 124-33
8. Roos A, Bouwman LH, Munoz J, et al: Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 2003; 39: 655-68
9. Frank MM: Complement deficiencies. In: Stites DP, Terr AI, Parslow TG (eds). Basic and Clinical Immunology. Beirut, Appleton and Lange, 1999; 309-11
10. Dahl MR, Thiel S, Matsushita M, et al: MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001; 15: 127-35
11. Podor TJ, Campbell S, Chindemi P, et al: Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. J Biol Chem 2002; 277: 7520-8
12. Miner JL, Hahn KJ, Spurlock ME, Staten NR: Expression and complement D activity of porcine adipsin. Protein Expr Purif 2001; 23: 14-21
13. Cianflone K, Roncari DA, Maslowska M, Baldo A, Forden J, Sniderman AD: Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994; 33: 9489-95
14. Murray I, Sniderman AD, Cianflone K: Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res 1999; 40: 1671-6
15. Koistinen HA, Vidal H, Karonen SL, et al: Plasma acylation stimulating protein concentration and subcutaneous adipose tissue mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 2001; 21: 1034-9
16. Halkes CJ, van Dijk H, de Jaegere PP, et al: Postprandial increase of complement 3 in normolipemic patients with coronary artey disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001; 21: 1526-30
17. Choy LN, Spiegelman BM: Regulation of alternative pathway activation and C3a production by adipose cells. Obes Res 1996; 4: 521-32
18. Cianflone K, Maslowska M: Differentiation-induced production of ASP in human adipocytes. Eur J Clin Invest 1995; 25: 817-25
19. Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 2002; 440: 213-21
20. Ukkola O, Santaniemi M: Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002; 80: 696-702
21. Pasqui AL, Puccetti L, Bova G, et al: Relationship between serum complement and different lipid disorders. Clin Exp Med 2002; 2: 33-8
22. Vakeva A, Jauhiainen M, Ehnholm C, Lehto T, Meri S: High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunology 1994; 82: 28-33
23. Ylitalo K, Pajukanta P, Meri S, et al: Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21: 838-43
24. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002; 161: 1-16
25. Pasqui AL, Bova G, Puccetti L, Bruni F, Pompella G, Auteri A: Complement activation in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2000; 10: 137-42
26. Choi-Miura NH, Sakamoto T, Tobe T, Nakano Y, Tomita M: The role of HDL consisting of SP-40, apo A-I, and lipids in the formation of SMAC of complement. J Biochem (Tokyo) 1993; 113: 484-7
27. Hamilton KK, Zhao J, Sims PJ: Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. J Biol Chem 1993; 268: 3632-8
28. Xu N, Dahlback B, Ohlin AK, Nilsson A: Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 1998; 18: 33-9
29. Sorace JM, Rollins S, Aniagolu JU, et al: Role of atheroma liposomes and malondialdehyde-modified low-density lipoproteins in complement activation. Pathobiology 1996; 64: 73-8
30. Wieland E, Dorweiler B, Bonitz U, Lieser S, Walev I, Bhakdi S: Complement activation by oxidatively modified low-density lipoproteins. Eur J Clin Invest 1999; 29: 835-41
31. Kildsgaard J, Zsigmond E, Chan L, Wetsel RA: A critical evaluation of the putative role of C3adesArg (ASP) in lipid metabolism and hyperapobetalipoproteinemia. Mol Immunol 1999; 36: 869-76
32. Furlan M: Sticky and promiscuous plasma proteins maintain the equilibrium between bleeding and thrombosis. Swiss Med Wkly 2002; 132: 181-9
33. Yarovaya GA, Blokhina TB, Neshkova EA: Contact system. New concepts on activation mechanisms and bioregulatory functions. Biochemistry (Mosc) 2002; 67: 13-24
34. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619-27
35. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y: C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-8
36. Bos IG, Hack CE, Abrahams JP: Structural and functional aspects of C1-inhibitor. Immunobiology 2002; 205: 518-33
37. Coppola L, Guastafierro S, Verrazzo G, Coppola A, De Lucia D, Tirelli A: C1 inhibitor infusion modifies platelet activity in hereditary angioedema patients. Arch Pathol Lab Med 2002; 126: 842-5
38. Peerschke EI, Jesty J, Reid KB, Ghebrehiwet B: The soluble recombinant form of a binding protein/receptor for the globular domain of C1q (gC1qR) enhances blood coagulation. Blood Coagul Fibrinolysis 1998; 9: 29-37
39. Ross R, Glomset JA: The Pathogenesis Of Atherosclerosis. New Engl J Med 1976; 295: 369-77
40. Seidel D: Significance of risk factors. In: Gotto AM Jr, Paoletti R (Eds). Atherosclerosis Reviews: Atherosclerosis Cellular Interactions, Growth Factors, and Lipids, Raven Press, 1993
41. Buono C, Come CE, Witztum JL, et al: Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025-31
42. Yasojima K, Schwab C, Mc Geer EG, Mc Geer PL: Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 1214-9
43. Torzewski J, Torzewski M, Bowyer DE, et al: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-92
44. Tanhehco EJ, Yasojima K, McGeer PL, Washington RA, Lucchesi BR: Free radicals upregulate complement expression in rabbit isolated heart. Am J Physiol Heart Circ Physiol 2000; 279: H195-201
45. Kashyap R, Floreani AA, Heires AJ, Sanderson SD, Wyatt TA: Protein kinase C-alpha mediates cigarette smoke extract- and complement factor 5a-stimulated interleukin-8 release in human bronchial epithelial cells. J Investig Med 2002; 50: 46-53
46. Veres A, Szamosi T, Ablonczy M, et al: Complement activating antibodies against the human 60 kDa heat shock protein as a new independent family risk factor of coronary heart disease. Eur J Clin Invest 2002; 32: 405-10
47. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res. 2002; 53: 31-47
48. Latini R, Masson S, Bertini R, Maggioni AP, Ghezzi P, Calvillo L: Cardiac protection by pharmacological modulation of inflammation. Expert Opin Investig Drugs. 2001; 10: 1913-24
49. Chakraborti T, Mandal A, Mandal M, Das S, Chakraborti S: Complement activation in heart diseases. Role of oxidants. Cell Signal. 2000; 12: 607-17
50. Ito BR, Del Balzo U: Effect of platelet depletion and inhibition of platelet cyclooxygenase on C5a-mediated myocardial ischemia. Am J Physiol. 1994; 267: H1288-94
51. Robert-Offerman SR, Leers MP, van Suylen RJ, Nap M, Daemen MJ, Theunissen PH: Evaluation of the membrane attack complex of complement for the detection of a recent myocardial infarction in man. J Pathol. 2000; 191: 48-53
52. Hoffmeister HM, Ehlers R, Buttcher E, et al: Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am J Cardiol. 2002; 89: 909-12
53. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al: Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997; 96: 3542-8
54. Sonoda M, Sakamoto K, Miyauchi T, et al: Changes in serum lipoprotein (a) and C4b-binding protein levels after acute myocardial infarction. Jpn Circ J 1992; 56: 1214-20
55. Muscari A, Bozzoli C, Puddu GM, et al: Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995; 98: 357-64
56. Csaszar A, Duba J, Melegh B, et al: Increased frequency of the C3*F allele and the Leiden mutation of coagulation factor V in patients with severe coronary heart disease who survived myocardial infarction. Exp Clin Immunogenet 2001; 18: 206-12
57. Nemeth A, Szakmary K, Kramer J, et al: Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Eur J Clin Chem Clin Biochem 1995; 33: 799-804
58. Faust D, Akoglu B, Zgouras D, Scheuermann EH, Milovic V, Stein J: Anti-inflammatory drugs modulate C1q secretion in human peritoneal macrophages in vitro. Biochem Pharmacol. 2002; 64: 457-62
59. Mason JC, Ahmed Z, Mankoff R, et al: Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002; 91: 696-703